Research use only, not for human consumption. Email [email protected]
← Research status explorer
Rebuild / Repair & longevity

KPV

Current research status Preclinical
Cellular and animal research
Preclinical

What is it?

KPV (Lys-Pro-Val) is a three-amino-acid peptide that corresponds to the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH 11-13), a hormone derived from proopiomelanocortin. It has been studied in laboratory and animal work for anti-inflammatory effects, particularly in intestinal inflammation (colitis) models, and in cell models of skin and airway inflammation. Reviews have noted that, unlike the parent hormone, the fragment is not described as having pigmentary activity. No clinical trials of KPV in people were identified.

Research overview

KPV is a tripeptide fragment of alpha-MSH studied for anti-inflammatory activity, primarily in cell culture and animal models of colitis, with some cell-based work on skin and airway inflammation. Public trial registries show no completed human clinical trials specifically for KPV at the time of writing.

Mechanism of action

In cell studies, KPV has been reported to reduce activation of the pro-inflammatory transcription factor NF-kB and of MAP kinase signalling, and to lower the secretion of pro-inflammatory cytokines. In human intestinal epithelial cells and a T-cell line, these effects were reported at nanomolar concentrations and were linked to uptake of the tripeptide through PepT1, a di/tripeptide transporter that is expressed in the small intestine and induced in the colon during inflammatory bowel disease [PMID 18061177]. In immortalised human bronchial epithelial cells, KPV was reported to be taken up into the nucleus, to stabilise IkB-alpha and to reduce nuclear translocation of the NF-kB subunit p65; the authors proposed an interaction with the importin-alpha binding site on p65 [PMID 22837805]. This is a proposed mechanism from a single cell-culture study.

Whether KPV acts through melanocortin receptors is unresolved. In a mouse peritonitis model, the anti-migratory effect of KPV was not blocked by a melanocortin 3/4 receptor antagonist, KPV did not raise cAMP in macrophages, and anti-inflammatory activity persisted in mice with a non-functional MC1R; the authors concluded KPV is unlikely to act through melanocortin receptors and may instead act through inhibition of IL-1beta functions [PMID 12750433]. A mouse colitis study likewise reported benefit that appeared at least partially independent of MC1R signalling [PMID 18092346]. Conversely, in human keratinocytes KPV did not raise cAMP but produced intracellular calcium responses, and it also did so in cells engineered to express MC1R [PMID 15102092]. These findings are not fully consistent with one another and the receptor question remains open.

A review of alpha-MSH and its related tripeptides summarises that alpha-MSH affects NF-kB activation, cytokine production and other inflammatory pathways, and describes the C-terminal tripeptide KPV as retaining anti-inflammatory activity without the pigmentary action of the full hormone [PMID 18612139]. Most of the mechanistic detail summarised above comes from in vitro work and rodent models, so it should be read as hypothesis-generating rather than established.

Adult human evidence

No studies in adult humans (18+) testing KPV as an administered compound were identified. PubMed searches combining KPV, Lys-Pro-Val and alpha-MSH(11-13) with terms such as patients, volunteers and clinical trial returned no clinical studies of KPV, and searches of ClinicalTrials.gov for KPV, KPV tripeptide, Lys-Pro-Val and KPV with colitis returned no registered studies of the peptide.

The only human-derived work found was laboratory work on human cells or samples, which is not clinical evidence. One ex vivo study reported that alpha-MSH(11-13) reduced LPS-induced IL-1 and TNF-alpha production in whole-blood samples taken from HIV-infected patients; the age of the donors is not stated in the abstract, and the work did not involve giving the peptide to people [PMID 9700761]. Human cell lines (intestinal, bronchial and keratinocyte) have also been used in the cell studies described under preclinical evidence [PMID 18061177, PMID 22837805].

Preclinical evidence

Colitis models (mouse). In mice, oral KPV in drinking water was reported to reduce the incidence of DSS- and TNBS-induced colitis, with lower pro-inflammatory cytokine expression [PMID 18061177]. A separate group reported that KPV treatment led to earlier recovery of body weight and fewer inflammatory infiltrates in DSS colitis and in a CD45RB-high T-cell transfer colitis model, and that all MC1R-deficient (e/e) mice treated with KPV survived DSS colitis [PMID 18092346]. In a colitis-associated cancer model (AOM/DSS), KPV was reported to prevent carcinogenesis in wild-type mice but not in PepT1-knockout mice, consistent with a PepT1-dependent action; the same study found that PepT1 overexpression increased, and PepT1 deletion decreased, tumour burden [PMID 27458604].

Delivery-system studies (mouse). Because free peptides are unstable in the gut, several studies have loaded KPV into nanoparticles. Nanoparticles embedded in an alginate-chitosan hydrogel were reported to protect mice in a DSS colitis model, with the authors stating that KPV was delivered at a concentration 12,000-fold lower than in free solution with similar efficacy [PMID 19909746]. Hyaluronic acid-functionalised nanoparticles in a hydrogel were reported to reduce mucosal damage and TNF-alpha in a mouse colitis model more than a non-targeted nanoparticle system [PMID 28143741]. These experiments test the delivery formulations as much as the peptide itself.

Other inflammation models. In a mouse crystal-induced peritonitis model, systemic KPV reduced accumulation of neutrophils (polymorphonuclear leukocytes), and was also active against IL-1beta-induced peritonitis [PMID 12750433]. In cultured human HaCaT keratinocytes exposed to fine particulate matter, KPV (50 ug/mL) was reported to restore cell viability, reduce reactive oxygen species and IL-1beta secretion, and suppress NF-kB, and to attenuate inflammatory cell death in a 3D skin model [PMID 40073467]. In immortalised human bronchial epithelial cells, KPV reduced NF-kB activity and IL-8 and eotaxin secretion [PMID 22837805]. These are cell-culture findings in a single laboratory each and have not been tested in people.

Evidence limitations

  • No clinical studies of KPV in adult humans were identified; all evidence for effects comes from cell culture, ex vivo samples and animals.
  • Most colitis work comes from a small number of research groups, uses chemically induced colitis in mice or rats, and reports results largely as relative changes in weight, histology and cytokine markers; sample sizes are often not stated in the abstracts.
  • Findings from rodent colitis models frequently do not carry over to human inflammatory bowel disease.
  • The mechanism is unsettled: PepT1-dependent uptake and NF-kB inhibition are reported, but whether melanocortin receptors are involved is contradictory across studies.
  • Many recent studies test KPV inside hydrogels, nanoparticles or drug co-assemblies, so effects of the peptide alone are difficult to separate from the delivery formulation.
  • Concentrations used in cell studies (for example 50 ug/mL in keratinocytes) and routes used in animals do not translate to any human exposure, and pharmacokinetics, stability and safety in people have not been characterised in the sources reviewed.
  • Skin and airway findings are from cultured cells only; no animal skin-disease model of KPV was verified for this dossier.

Research and regulatory status

KPV is at the preclinical stage: published work consists of cell-culture and animal studies, mainly in colitis models, with additional cell-based work on skin and airway inflammation. Searches of PubMed and ClinicalTrials.gov did not identify any clinical trial of KPV in humans. It is not an approved medicine.

Key studies

Preclinical (animal / cell)

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. · Gastroenterology · 2008

Design
Cell culture plus mouse colitis models (DSS and TNBS)
Participants / model
Human intestinal epithelial cells (Caco2-BBE, HT29-Cl.19A), human T cells (Jurkat), and mice with DSS- or TNBS-induced colitis
Sample size
not stated in the abstract
Principal findings
Nanomolar KPV was reported to inhibit NF-kB and MAP kinase signalling and reduce pro-inflammatory cytokine secretion, with uptake through PepT1. Oral KPV reduced the incidence of DSS- and TNBS-induced colitis and cytokine expression in mice.
Limitations
Abstract does not give group sizes; chemically induced mouse colitis only, and the authors' conclusion about IBD therapy is speculative without human data.

PubMed 18061177 DOI 10.1053/j.gastro.2007.10.026

Preclinical (animal / cell)

Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.

Kannengiesser K, Maaser C, Heidemann J, et al. · Inflammatory bowel diseases · 2008

Design
Mouse colitis models (DSS colitis and CD45RB-high transfer colitis)
Participants / model
Mice, including animals with a nonfunctional melanocortin-1 receptor (MC1R e/e)
Sample size
not stated in the abstract
Principal findings
KPV was reported to give earlier recovery and greater regain of body weight, fewer histological inflammatory infiltrates and lower colonic MPO activity in DSS colitis, with similar benefit in transfer colitis. All treated MC1R e/e mice survived DSS colitis, and the authors concluded effects were at least partially independent of MC1R signalling.
Limitations
Group sizes not stated in the abstract; murine models only, and mechanism was not directly defined.

PubMed 18092346 DOI 10.1002/ibd.20334

Preclinical (animal / cell)

Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.

Laroui H, Dalmasso G, Nguyen HT, et al. · Gastroenterology · 2010

Design
Nanoparticle formulation study with cell culture and mouse DSS colitis model
Participants / model
Caco2-BBE cells and mice with DSS-induced colitis
Sample size
not stated in the abstract
Principal findings
KPV-loaded nanoparticles in an alginate-chitosan hydrogel reduced inflammatory responses to LPS in Caco2-BBE cells and protected mice against inflammatory and histological parameters in DSS colitis. The authors reported KPV could be delivered at a concentration 12,000-fold lower than in free solution with similar efficacy.
Limitations
Tests a delivery formulation, so effects of the peptide cannot be separated from the carrier; mouse model and no human data.

PubMed 19909746 DOI 10.1053/j.gastro.2009.11.003

Preclinical (animal / cell)

Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.

Xiao B, Xu Z, Viennois E, et al. · Molecular therapy : the journal of the American Society of Gene Therapy · 2017

Design
Nanoparticle formulation study with cell culture and mouse colitis model
Participants / model
Colonic epithelial cells, macrophages, and a mouse model of ulcerative colitis
Sample size
not stated in the abstract
Principal findings
Hyaluronic acid-functionalised KPV nanoparticles delivered in a chitosan/alginate hydrogel were reported to prevent mucosal damage and downregulate TNF-alpha in a mouse colitis model, with greater effect than KPV nanoparticles without the hyaluronic acid.
Limitations
Formulation-focused study in mice; comparison was with another nanoparticle system and the abstract does not give sample sizes.

PubMed 28143741 DOI 10.1016/j.ymthe.2016.11.020

Preclinical (animal / cell)

Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.

Viennois E, Ingersoll SA, Ayyadurai S, et al. · Cellular and molecular gastroenterology and hepatology · 2016

Design
Mouse colitis-associated cancer model (AOM/DSS) with transgenic and knockout mice; human biopsy analysis of PepT1 expression
Participants / model
Wild-type, intestinal hPepT1-overexpressing and PepT1-knockout mice; human colonic biopsies (for PepT1 expression only)
Sample size
not stated in the abstract
Principal findings
PepT1 overexpression increased, and PepT1 deletion decreased, tumour burden and inflammation. KPV was reported to prevent carcinogenesis in wild-type mice but had no inhibitory effect in PepT1-knockout mice. PepT1 expression was higher in biopsies from patients with colorectal cancer; KPV itself was not given to humans.
Limitations
Mouse model; the human component measured PepT1 expression, not KPV effects. The primary focus is PepT1 biology rather than KPV.

PubMed 27458604 DOI 10.1016/j.jcmgh.2016.01.006

Preclinical (animal / cell)

Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.

Getting SJ, Schiöth HB, Perretti M · The Journal of pharmacology and experimental therapeutics · 2003

Design
Mouse peritonitis models and in vitro macrophage experiments
Participants / model
Mice (including MC1R-nonfunctional recessive yellow e/e mice) and macrophages
Sample size
not stated in the abstract
Principal findings
Systemic KPV reduced neutrophil accumulation in crystal-induced and IL-1beta-induced peritonitis, and its effect was not blocked by an MC3/4 receptor antagonist. KPV did not inhibit macrophage cytokine release in vitro or raise cAMP. The authors concluded KPV is unlikely to act through melanocortin receptors and may act through inhibition of IL-1beta functions.
Limitations
Acute peritonitis model with a short observation window; the proposed IL-1beta mechanism is an interpretation, not directly demonstrated in the abstract.

PubMed 12750433 DOI 10.1124/jpet.103.051623

Preclinical (animal / cell)

Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.

Land SC · International journal of physiology, pathophysiology and pharmacology · 2012

Design
Cell culture (immortalised human bronchial epithelial cell line)
Participants / model
16HBE14o- human bronchial epithelial cells stimulated with TNF-alpha or respiratory syncytial virus
Sample size
not stated in the abstract
Principal findings
KPV was reported to dose-dependently inhibit NF-kB activity, MMP-9 activity and IL-8 and eotaxin secretion, associated with nuclear import of KPV, IkB-alpha stabilisation and reduced nuclear translocation of p65RelA. Competition assays suggested an interaction with the importin-alpha binding site on p65RelA.
Limitations
Single cell line in vitro; the proposed p65 importin-binding mechanism comes from competition assays and has not been confirmed in animals or people.

PubMed 22837805

Preclinical (animal / cell)

alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.

Elliott RJ, Szabo M, Wagner MJ, et al. · The Journal of investigative dermatology · 2004

Design
Cell culture signalling study
Participants / model
HaCaT and normal human keratinocytes, and CHO cells stably expressing MC-1R
Sample size
not stated in the abstract
Principal findings
No rise in cyclic AMP was detected in keratinocytes in response to alpha-MSH, KPV or ACTH peptides. Intracellular calcium responses were observed with KPV (in the presence of the adenosine agonist PIA) and in MC-1R-transfected CHO cells.
Limitations
In vitro signalling only; it does not show an anti-inflammatory outcome, and the receptor mechanism remains unresolved.

PubMed 15102092 DOI 10.1111/j.0022-202X.2004.22404.x

Preclinical (animal / cell)

Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.

Sung J, Ju SY, Park S, et al. · Tissue & cell · 2025

Design
Cell culture and 3D skin model
Participants / model
Human HaCaT keratinocytes exposed to fine particulate matter (PM10), and a 3D skin model
Sample size
not stated in the abstract
Principal findings
KPV (50 ug/mL) was reported to restore cell viability, reduce ROS and IL-1beta secretion, and decrease expression of apoptosis-related proteins via suppression of NF-kB in PM10-treated keratinocytes, and to attenuate inflammatory cell death in a 3D skin model.
Limitations
In vitro model of particulate-matter exposure using a high peptide concentration; no animal or human skin data, and the abstract's mention of cosmetic applications is speculative.

PubMed 40073467 DOI 10.1016/j.tice.2025.102837

Preclinical (animal / cell)

Melanocortin peptides inhibit production of proinflammatory cytokines in blood of HIV-infected patients.

Catania A, Garofalo L, Cutuli M, et al. · Peptides · 1998

Design
Ex vivo human whole-blood experiments (laboratory study, no administration to participants)
Participants / model
Whole blood samples from HIV-infected patients and normal peripheral blood mononuclear cells
Sample size
not stated in the abstract
Principal findings
In LPS-stimulated whole blood from HIV patients, alpha-MSH(1-13), alpha-MSH(11-13) (KPV), ACTH(1-24) and ACTH(1-39) were reported to reduce IL-1 and TNF-alpha production in a concentration-dependent manner.
Limitations
Ex vivo laboratory work on blood samples, not a clinical study; donor numbers and ages are not stated in the abstract and KPV was not given to patients.

PubMed 9700761 DOI 10.1016/s0196-9781(98)00055-2

Review

Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.

Brzoska T, Luger TA, Maaser C, et al. · Endocrine reviews · 2008

Design
Narrative review
Participants / model
Review of in vitro and animal literature on alpha-MSH and the tripeptides KPV and KdPT
Sample size
not applicable
Principal findings
The review summarises that alpha-MSH affects NF-kB activation, cytokine production and other inflammatory pathways, and that KPV retains anti-inflammatory effect without the pigmentary action of alpha-MSH. The authors state that the tripeptides may be suitable for future treatment of immune-mediated inflammatory diseases.
Limitations
Narrative review published in 2008, so later work is not covered; authors' forward-looking statements about therapy are not supported by human trials.

PubMed 18612139 DOI 10.1210/er.2007-0027

Last reviewed: 20 November 2026